Skip to content
Clinical Trials – home

Fondazione I.R.C.C.S. Istituto Neurologico Besta

Verified siteinfo

Italy Via Giacomo Venezian 1, 20133 Milan, Italy

  • 314 trials recruiting
  • Non-small cell lung cancer · Neoplasm · Neoplasm malignant
  • Adults and children

About Specializations

Fondazione I.R.C.C.S. Istituto Neurologico Besta in Milan, Italy specialises in clinical trials of conditions such as Non-small cell lung cancer, Neoplasm, Neoplasm malignant, Colorectal cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Nervous System Diseases and Epilepsy Research

At Fondazione I.R.C.C.S. Istituto Neurologico Besta, clinical trials in Nervous System Diseases focus on focal epilepsy, with research aimed at improving seizure control and understanding how new therapies may benefit adults living with ongoing seizures.

  • Studying focal epilepsy as part of broader neurological research
  • Evaluating the effectiveness of new treatment options for seizure frequency
  • Supporting better care for adults already using anti-seizure medicines

The site’s work in SC Neurologia 7 reflects a strong clinical interest in testing whether emerging therapies can offer improved symptom control and safety for people with difficult-to-manage epilepsy.

Clinical Research in Neurology

This health care research center in Milan is conducting studies centered on focal seizures, with a clear emphasis on assessing treatment effectiveness and advancing practical options for patients with chronic neurological conditions.

  • Primary focus on focal seizure disorders
  • Exploring new approaches to reduce seizure burden
  • Generating evidence to guide future epilepsy treatment

Across its trials, the institute is contributing to research that may help clarify how novel therapies compare with existing care in adults with persistent epilepsy.

Therapy Evaluation in Epilepsy

The clinical trial portfolio at this Italian neurological institute includes work designed to test a new therapy for focal epilepsy, aiming to determine whether it can improve seizure outcomes for adults receiving standard background treatment.

  • Epilepsy treatment evaluation
  • Focal seizures and symptom control
  • Comparing investigational care with existing standard therapy

These studies support ongoing efforts to expand options for patients whose seizures remain a challenge despite current medicines.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Giacomo Venezian 120133 MilanItaly
Recruiting now
314 trials
Conditions studied
296
Partner status
Verified site

More sites in MilanItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

738 clinical trials

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Breast cancer

Recruiting

Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BioNTech SE

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.

Uveal melanoma

Recruiting

A Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Darovasertib
  • Sponsor:Ideaya Biosciences Inc.

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Study of GSK5764227 alone and in combination for patients with previously treated advanced gastrointestinal tumors that cannot be removed by surgery or have spread

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dimeticone
  • Sponsor:Novartis Pharma AG

Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.